prikaz prve stranice dokumenta Keratin 13 Expression Reprograms bone and Brain Metastases of Human Prostate Cancer Cells
  Preuzmi
PDF 11.56 MB
Znanstveni rad - Izvorni znanstveni rad
Keratin 13 Expression Reprograms bone and Brain Metastases of Human Prostate Cancer Cells
Oncotarget, 7 (2016), 51; 84645-84657. https://doi.org/10.18632/oncotarget.13175.
Li, Qinlong; Yin, Lijuan; Jones, Lawrence W.; Chu, Gina C-Y; Wu, Jason B-Y.; Huang, Jen-Ming; Li, Quanlin; You, Sungyong; Kim, Jayoung; Lu, Yi-Tsung; Mrđenović, Stefan; Wang, Ruoxiang; Freeman, Michael R.; Garraway, Isla; Lewis, Michael S.; Chung, Leland W. K.; Zhau, Haiyen E. Više autora...

Citirajte ovaj rad

Li, Q., Yin, L., Jones, L. W., Chu, G. C. Y., Wu, J. B. Y., Huang, J. M. ... Zhau, H. E. (2016). Keratin 13 Expression Reprograms bone and Brain Metastases of Human Prostate Cancer Cells. Oncotarget, 7. (51), 84645-84657. doi: 10.18632/oncotarget.13175.

Li, Qinlong, et al. "Keratin 13 Expression Reprograms bone and Brain Metastases of Human Prostate Cancer Cells." Oncotarget, vol. 7, br. 51, 2016, str. 84645-84657. https://doi.org/10.18632/oncotarget.13175.

Li, Qinlong, Lijuan Yin, Lawrence W. Jones, Gina C Y Chu, Jason B Y. Wu, Jen Ming Huang, Quanlin Li, et al. "Keratin 13 Expression Reprograms bone and Brain Metastases of Human Prostate Cancer Cells." Oncotarget 7, br. 51 (2016): 84645-84657. https://doi.org/10.18632/oncotarget.13175.

Li, Q., et al. (2016) 'Keratin 13 Expression Reprograms bone and Brain Metastases of Human Prostate Cancer Cells', Oncotarget, 7(51), str. 84645-84657. doi: 10.18632/oncotarget.13175.

Li Q, Yin L, Jones LW, Chu GCY, Wu JBY, Huang JM, i sur.. Keratin 13 Expression Reprograms bone and Brain Metastases of Human Prostate Cancer Cells. Oncotarget [Internet]. 2016. [pristupljeno 05.10.2024.];7(51):84645-84657. doi: 10.18632/oncotarget.13175.

Q. Li, et al., "Keratin 13 Expression Reprograms bone and Brain Metastases of Human Prostate Cancer Cells", Oncotarget, vol. 7, br. 51, str. 84645-84657, 2016. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:239:232835. [Citirano: 05.10.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:239:232835
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Keratin 13 Expression Reprograms bone and Brain Metastases of Human Prostate Cancer Cells
AutorQinlong Li
AutorLijuan Yin
AutorLawrence W. Jones
AutorGina C-Y Chu
AutorJason B-Y. Wu
AutorJen-Ming Huang
AutorQuanlin Li
AutorSungyong You
AutorJayoung Kim
AutorYi-Tsung Lu
AutorStefan Mrđenović
MBZ: 103524
AutorRuoxiang Wang
AutorMichael R. Freeman
AutorIsla Garraway
AutorMichael S. Lewis
AutorLeland W. K. Chung
AutorHaiyen E. Zhau
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Onkologija
Sažetak (engleski)
Lethal progression of prostate cancer metastasis can be improved by developing animal models that recapitulate the clinical conditions. We report here that cytokeratin 13 (KRT13), an intermediate filament protein, plays a directive role in prostate cancer bone, brain, and soft tissue metastases. KRT13 expression was elevated in bone, brain, and soft tissue metastatic prostate cancer cell lines and in primary and metastatic clinical prostate, lung, and breast cancer specimens. When KRT13 expression was determined at a single cell level in primary tumor tissues of 44 prostate cancer cases, KRT13 level predicted bone metastasis and the overall survival of prostate cancer patients. Genetically enforced KRT13 expression in human prostate cancer cell lines drove metastases toward mouse bone, brain and soft tissues through a RANKL-independent mechanism, as KRT13 altered the expression of genes associated with EMT, stemness, neuroendocrine/neuromimicry, osteomimicry, development, and extracellular matrices, but not receptor activator NF-κB ligand (RANKL) signaling networks in prostate cancer cells. Our results suggest new inhibitors targeting RANKL-independent pathways should be developed for the treatment of prostate cancer bone and soft tissue metastases.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaOncotarget
Brojčani podacivol. 7, br. 51, str. 84645-84657
e-ISSN1949-2553
DOIhttps://doi.org/10.18632/oncotarget.13175.
URN:NBNurn:nbn:hr:239:232835
Datum objave publikacije2016
URL dokumentahttp://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=13175&path[]=41769
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 3.0 (CC BY 3.0)
Datum i vrijeme pohrane2019-11-27 12:07:03